A Double-Blind, Placebo-Controlled, Flexible-Dose Study of Vilazodone in Patients With Generalized Anxiety Disorder.
Phase of Trial: Phase III
Latest Information Update: 24 May 2017
At a glance
- Drugs Vilazodone (Primary)
- Indications Anxiety disorders
- Focus Registrational; Therapeutic Use
- Sponsors Forest Laboratories
- 24 May 2016 Results published in the Journal of Clinical Psychiatry
- 31 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 01 May 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.